Pioneers in patient-based
drug discovery
From Patient to drug:
Human Patient derived drug candidates for next generation medicines.
At Ksilink, we design and apply patient-based cellular disease models and other complex cellular systems applicable for large-scale phenotypic screening to support partners, customers and our in house programs. Our proprietary drug discovery engine applies unique AI-boosted cellular profiling technologies to identify druggable targets and develop the most efficient compounds for novel treatment options.
Given the rising costs of drug discovery combined with high failure rates in late-stage clinical development, our proprietary pipeline of patient-based drug discovery programs aims at derisking next generation medicine for neurologic diseases with high medical need.
In addition, we also engage with partners and customers to develop tailor made solutions based on our unique capability in handling a broad range of complex cellular systems. Based on our expertise in microscope based read out systems, we develop assays systems, solutions for high throughput phenotypic screening approaches or complete package solutions from assay development up to target identification for relevant hit molecules.
Newsroom
Keep posted about
our latest developments
and achievements
Meet us in Basel!
This year, Ksilink will be present at several key partnering and business conferences. Curious about our cutting-edge work in disease modeling, AI-driven image analysis for assay...
We are thrilled to announce the arrival of our new Chief Operating Officer!
Dr Helmut Haning has recently joined the management of Ksilink as COO, complementing the team with a longstanding experience in pharmaceutical drug discovery. He brings to the...
Join Ksilink at BIO Partnering @ JPM Week 2025!
We are excited to announce that Mona Boyé, Head of BD & Partnerships, and Johannes Wilbertz, Team Leader Neuroscience, will be attending BIO Partnering @ JPM Week in San...